Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shandong Weigao Blood Purification Products Co (SHSE:603014) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Shandong Weigao Blood Purification Products Co Forward PE Ratio Related Terms
Shandong Weigao Blood Purification Products Co Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Blood Purification Products Co Forward PE Ratio Chart
Shandong Weigao Blood Purification Products Co Annual Data
Trend
2025-12
Forward PE Ratio
31.42
Shandong Weigao Blood Purification Products Co Quarterly Data
2025-12
2026-03
2026-06
Forward PE Ratio
31.42
30.30
26.42
SHSE:603014 vs ABT, SYK, MDT: Forward PE Ratio Comparison
For the Medical Devices subindustry, Shandong Weigao Blood Purification Products Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Weigao Blood Purification Products Co Forward PE Ratio vs Medical Devices & Instruments Industry
Shandong Weigao Blood Purification Products Co Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a Forward PE Ratio of 22.77 as of Sep. 21, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. According to the industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #262 out of 403 companies in the Medical Devices & Instruments industry, placing it in the top 65%.
Is Shandong Weigao Blood Purification Products Co's Forward PE Ratio too high?
Shandong Weigao Blood Purification Products Co's current Forward PE Ratio is 22.77. The Medical Devices & Instruments industry median Forward PE Ratio is 17.64. Shandong Weigao Blood Purification Products Co's value of 22.77 is 29.1% above this industry median. Based on the distribution chart, Shandong Weigao Blood Purification Products Co ranks #262 out of 403 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Shandong Weigao Blood Purification Products Co has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Blood Purification Products Co's Forward PE Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #262 out of 403 companies for Forward PE Ratio. This places Shandong Weigao Blood Purification Products Co in the lower half of its industry. The industry median Forward PE Ratio is 17.64. Shandong Weigao Blood Purification Products Co's value of 22.77 is 29.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 17.64, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Weigao Blood Purification Products Co's current Forward PE Ratio of 22.77 is 29.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 17.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Weigao Blood Purification Products Co's current Forward PE Ratio is 22.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Blood Purification Products Co stock overvalued right now?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a current Forward PE Ratio of 22.77. The current Forward PE Ratio is 22.77 and 29.1% above the Medical Devices & Instruments industry median of 17.64. Shandong Weigao Blood Purification Products Co's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Shandong Weigao Blood Purification Products Co (SHSE:603014), the current Forward PE Ratio is 22.77 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603014 has been successfully added to your 
